Gypenoside XLIX Alleviates Diclofenac‐Induced Hepatotoxicity via Modulating Akt/NLRP3 Pathway
Journal of Biochemical and Molecular Toxicology · 2026
DOI: 10.1002/jbt.70686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Mingkai Yao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traumatology, The 964th Hospital of PLA Joint Logistic Support Force, Changchun, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Chemical and Drug Induced Liver Injury, NLR Family, Pyrin Domain-Containing 3 Protein, Diclofenac. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Drug‐induced liver injury (DILI) represents a critical pharmacotherapeutic challenge requiring novel interventions. The hepatoprotective mechanisms of Gypenoside XLIX (GYP XLIX) against liver injury remain underexplored. This study establishes GYP XLIX as a hepatoprotective agent against diclofenac (DF)‐induced liver injury through integrated experimental approaches. Male Wistar rats were used in this investigation and grouped randomly into four groups: the control group, the DF group (50 mg/kg), the GYP XLIX group (30 mg/kg), the DF + XLIX group, and the DF + silymarin group for 7 days. Human liver cell line L02 was used for further study. The analytical methods used included network pharmacology analysis, molecular docking, H&E staining, qPCR, enzyme activity assay, and Western blot. GYP XLIX significantly ameliorated DF‐induced hepatic damage, as evidenced by reduced serum ALT, AST, and ALP levels, attenuated histopathological abnormalities, enhanced antioxidant capacity (elevated SOD and GSH, decreased MDA), and suppressed pro‐inflammatory cytokine release. Mechanistically, GYP XLIX targeted the AKT/NLRP3 pathway, promoting AKT phosphorylation and inhibiting NLRP3 inflammasome activation, confirming its role in alleviating hepatotoxicity through antioxidative and anti‐inflammatory mechanisms. In L02 cells, GYP XLIX exerts a protective effect against DF‐induced liver injury through the AKT/NLRP3 axis, and this mechanism has been further confirmed. This work supports GYP XLIX as a promising multi‐target therapeutic candidate for chemical hepatotoxicity, providing new insights for clinical prevention and treatment of DILI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traumatology, The 964th Hospital of PLA Joint Logistic Support Force, Changchun, China.
ORCID-Profile: Ziting Yang
Zitieren
APA
Yao, M., Duan, D., Zhang, X., Tang, G., Cui, H., & Yang, Z. (2026). Gypenoside XLIX Alleviates Diclofenac‐Induced Hepatotoxicity via Modulating Akt/NLRP3 Pathway. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70686
Vancouver
Yao M, Duan D, Zhang X, Tang G, Cui H, Yang Z. Gypenoside XLIX Alleviates Diclofenac‐Induced Hepatotoxicity via Modulating Akt/NLRP3 Pathway. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.70686
BibTeX
@article{Yao2026,
author = {Yao, Mingkai and Duan, Daxin and Zhang, Xin and Tang, Guoqiang and Cui, Haifeng and Yang, Ziting},
title = {Gypenoside XLIX Alleviates Diclofenac‐Induced Hepatotoxicity via Modulating Akt/NLRP3 Pathway},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
doi = {10.1002/jbt.70686}
}
EUVIMED